Amoy Diagnostics Co Ltd
SZSE:300685

Watchlist Manager
Amoy Diagnostics Co Ltd Logo
Amoy Diagnostics Co Ltd
SZSE:300685
Watchlist
Price: 21.03 CNY 2.19% Market Closed
Market Cap: 8.3B CNY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Amoy Diagnostics Co Ltd stock under the Base Case scenario is 33.22 CNY. Compared to the current market price of 21.03 CNY, Amoy Diagnostics Co Ltd is Undervalued by 37%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
33.22 CNY
Undervaluation 37%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

7.3
P/S
P/S
Price to Sales
7.3
vs History
90
vs Industry
49
Median 3Y
9.3
Median 5Y
11.5
Industry
6.7
Forward
6.1
More Details
29.8
P/E
P/E
Price to Earnings
29.8
vs History
90
vs Industry
6
Median 3Y
33.5
Median 5Y
41.3
Industry
21.9
Forward
21.9
More Details
23
P/OCF
P/OCF
Price to OCF
23
vs History
98
vs Industry
6
Median 3Y
32.8
Median 5Y
45.3
Industry
19.2
More Details
26.1
P/FCFE
P/FCFE
Price to FCFE
26.1
vs History
98
vs Industry
7
Median 3Y
40
Median 5Y
60.1
Industry
22.5
More Details
4.5
P/B
P/B
Price to Book Value
4.5
vs History
90
vs Industry
19
Median 3Y
5.5
Median 5Y
7.1
Industry
2.4
More Details
6.3
EV/S
EV/S
Enterprise Value to Sales
6.3
vs History
90
vs Industry
43
Median 3Y
8.4
Median 5Y
10.7
Industry
7.1
Forward
5.3
More Details
7.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.5
vs History
90
vs Industry
45
Median 3Y
10.2
Median 5Y
12.8
Industry
9
More Details
25
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
25
vs History
90
vs Industry
6
Median 3Y
35.7
Median 5Y
42.8
Industry
3.7
Forward
16.4
More Details
25
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
25
vs History
90
vs Industry
6
Median 3Y
35.7
Median 5Y
42.8
Industry
3.4
Forward
17.4
More Details
19.8
EV/OCF
EV/OCF
Enterprise Value to OCF
19.8
vs History
98
vs Industry
7
Median 3Y
29.7
Median 5Y
43.3
Industry
4.3
More Details
22.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
22.4
vs History
98
vs Industry
5
Median 3Y
35.9
Median 5Y
65.8
Industry
3.4
More Details
8.3
EV/IC
EV/IC
Enterprise Value to IC
8.3
vs History
85
vs Industry
21
Median 3Y
9.3
Median 5Y
11.3
Industry
4.5
More Details

Multiples Across Competitors

Competitors Multiples
Amoy Diagnostics Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Amoy Diagnostics Co Ltd
SZSE:300685
8.4B CNY 7.3 29.8 25 25
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 726 371.3 -169 802.1 -206 193.9 -203 841
US
Abbvie Inc
NYSE:ABBV
331.3B USD 5.9 78 15.5 23.4
US
Amgen Inc
NASDAQ:AMGN
145.5B USD 4.3 24.5 13.4 22.2
US
Gilead Sciences Inc
NASDAQ:GILD
127.1B USD 4.4 21.3 9.3 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111.9B USD 10.1 -113.1 24 25.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 971.9 -503.2 -547.9 -533.3
AU
CSL Ltd
ASX:CSL
116.6B AUD 4.9 27.1 16.7 20.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.9B USD 4.3 13.5 12.1 13.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
34.5B USD 14.6 -127.9 -569.1 -285.2
NL
argenx SE
XBRU:ARGX
30.3B EUR 15.3 40.1 -2 283.2 -1 530.7
P/E Multiple
Earnings Growth PEG
CN
Amoy Diagnostics Co Ltd
SZSE:300685
Average P/E: 33.5
29.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -169 802.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
78
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.5
44%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
21.3
187%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -113.1 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -503.2 N/A N/A
AU
CSL Ltd
ASX:CSL
27.1
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
10%
1.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -127.9 N/A N/A
NL
argenx SE
XBRU:ARGX
40.1
28%
1.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Amoy Diagnostics Co Ltd
SZSE:300685
Average EV/EBITDA: 16.6
25
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -206 193.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.3
7%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
18%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -547.9 N/A N/A
AU
CSL Ltd
ASX:CSL
16.7
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.1
14%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -569.1 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 283.2 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Amoy Diagnostics Co Ltd
SZSE:300685
Average EV/EBIT: 20.4
25
29%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -203 841 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.2
31%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.1
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.3 N/A N/A
AU
CSL Ltd
ASX:CSL
20.9
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
13%
1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -285.2 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 530.7 N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 254,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.